Arcturus Therapeutics (ARCT) Competitors

$7.47 -0.36 (-4.60%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$7.52 +0.06 (+0.74%)

As of 05/15/2026 06:26 PM Eastern

ARCT vs. CVAC, AKTS, ALVO, PHAT, and SDGR

Should you buy Arcturus Therapeutics stock or one of its competitors? MarketBeat compares Arcturus Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Arcturus Therapeutics include CureVac (CVAC), Aktis Oncology (AKTS), Alvotech (ALVO), Phathom Pharmaceuticals (PHAT), and Schrodinger (SDGR). These companies are all part of the "pharmaceutical products" industry.

How does Arcturus Therapeutics compare to CureVac?

CureVac (NASDAQ:CVAC) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

CureVac has higher earnings, but lower revenue than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Arcturus Therapeutics	$82.03M	2.59	-$65.78M	-$2.81	N/A

CureVac has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market. Comparatively, Arcturus Therapeutics has a beta of 2.43, indicating that its share price is 143% more volatile than the broader market.

CureVac has a net margin of 199.92% compared to Arcturus Therapeutics' net margin of -143.80%. CureVac's return on equity of -23.03% beat Arcturus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Arcturus Therapeutics	-143.80%	-36.55%	-28.40%

CureVac presently has a consensus target price of $6.83, indicating a potential upside of 46.64%. Arcturus Therapeutics has a consensus target price of $25.44, indicating a potential upside of 240.62%. Given Arcturus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Arcturus Therapeutics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Arcturus Therapeutics had 10 more articles in the media than CureVac. MarketBeat recorded 10 mentions for Arcturus Therapeutics and 0 mentions for CureVac. CureVac's average media sentiment score of 0.00 beat Arcturus Therapeutics' score of -0.01 indicating that CureVac is being referred to more favorably in the media.

Company	Overall Sentiment
CureVac	Neutral
Arcturus Therapeutics	Neutral

17.3% of CureVac shares are held by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are held by institutional investors. 2.2% of CureVac shares are held by insiders. Comparatively, 17.8% of Arcturus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Arcturus Therapeutics beats CureVac on 9 of the 17 factors compared between the two stocks.

How does Arcturus Therapeutics compare to Aktis Oncology?

Arcturus Therapeutics (NASDAQ:ARCT) and Aktis Oncology (NASDAQ:AKTS) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

In the previous week, Arcturus Therapeutics had 3 more articles in the media than Aktis Oncology. MarketBeat recorded 10 mentions for Arcturus Therapeutics and 7 mentions for Aktis Oncology. Arcturus Therapeutics' average media sentiment score of -0.01 beat Aktis Oncology's score of -0.16 indicating that Arcturus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcturus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aktis Oncology	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Aktis Oncology has lower revenue, but higher earnings than Arcturus Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcturus Therapeutics	$82.03M	2.59	-$65.78M	-$2.81	N/A
Aktis Oncology	$6.50M	160.61	N/A	N/A	N/A

Arcturus Therapeutics currently has a consensus price target of $25.44, suggesting a potential upside of 240.62%. Aktis Oncology has a consensus price target of $32.00, suggesting a potential upside of 63.68%. Given Arcturus Therapeutics' higher probable upside, equities research analysts clearly believe Arcturus Therapeutics is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.67
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

94.5% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are owned by institutional investors. 17.8% of Arcturus Therapeutics shares are owned by insiders. Comparatively, 3.3% of Aktis Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Aktis Oncology has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -143.80%. Aktis Oncology's return on equity of 0.00% beat Arcturus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcturus Therapeutics	-143.80%	-36.55%	-28.40%
Aktis Oncology	N/A	N/A	N/A

Summary

Arcturus Therapeutics beats Aktis Oncology on 8 of the 13 factors compared between the two stocks.

How does Arcturus Therapeutics compare to Alvotech?

Arcturus Therapeutics (NASDAQ:ARCT) and Alvotech (NASDAQ:ALVO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Alvotech has higher revenue and earnings than Arcturus Therapeutics. Alvotech is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcturus Therapeutics	$82.03M	2.59	-$65.78M	-$2.81	N/A
Alvotech	$588.90M	1.70	$27.92M	-$0.25	N/A

Arcturus Therapeutics currently has a consensus price target of $25.44, suggesting a potential upside of 240.62%. Alvotech has a consensus price target of $7.60, suggesting a potential upside of 129.61%. Given Arcturus Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Arcturus Therapeutics is more favorable than Alvotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.67
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

94.5% of Arcturus Therapeutics shares are owned by institutional investors. 17.8% of Arcturus Therapeutics shares are owned by insiders. Comparatively, 0.5% of Alvotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Alvotech has a net margin of -14.36% compared to Arcturus Therapeutics' net margin of -143.80%. Alvotech's return on equity of -11.92% beat Arcturus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcturus Therapeutics	-143.80%	-36.55%	-28.40%
Alvotech	-14.36%	-11.92%	-7.58%

Arcturus Therapeutics has a beta of 2.43, meaning that its share price is 143% more volatile than the broader market. Comparatively, Alvotech has a beta of 0.21, meaning that its share price is 79% less volatile than the broader market.

In the previous week, Arcturus Therapeutics had 2 more articles in the media than Alvotech. MarketBeat recorded 10 mentions for Arcturus Therapeutics and 8 mentions for Alvotech. Alvotech's average media sentiment score of 0.24 beat Arcturus Therapeutics' score of -0.01 indicating that Alvotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcturus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alvotech	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Arcturus Therapeutics beats Alvotech on 10 of the 17 factors compared between the two stocks.

How does Arcturus Therapeutics compare to Phathom Pharmaceuticals?

Arcturus Therapeutics (NASDAQ:ARCT) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Arcturus Therapeutics has higher earnings, but lower revenue than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcturus Therapeutics	$82.03M	2.59	-$65.78M	-$2.81	N/A
Phathom Pharmaceuticals	$204.89M	4.62	-$221.25M	-$2.12	N/A

Arcturus Therapeutics currently has a consensus price target of $25.44, suggesting a potential upside of 240.62%. Phathom Pharmaceuticals has a consensus price target of $25.00, suggesting a potential upside of 110.61%. Given Arcturus Therapeutics' higher possible upside, research analysts plainly believe Arcturus Therapeutics is more favorable than Phathom Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.67
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

94.5% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 17.8% of Arcturus Therapeutics shares are owned by insiders. Comparatively, 9.3% of Phathom Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Phathom Pharmaceuticals has a net margin of -76.77% compared to Arcturus Therapeutics' net margin of -143.80%. Phathom Pharmaceuticals' return on equity of 0.00% beat Arcturus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcturus Therapeutics	-143.80%	-36.55%	-28.40%
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%

Arcturus Therapeutics has a beta of 2.43, meaning that its share price is 143% more volatile than the broader market. Comparatively, Phathom Pharmaceuticals has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market.

In the previous week, Arcturus Therapeutics had 7 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 10 mentions for Arcturus Therapeutics and 3 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 1.10 beat Arcturus Therapeutics' score of -0.01 indicating that Phathom Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcturus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Phathom Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Arcturus Therapeutics and Phathom Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Arcturus Therapeutics compare to Schrodinger?

Schrodinger (NASDAQ:SDGR) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk.

Schrodinger presently has a consensus price target of $20.25, suggesting a potential upside of 69.46%. Arcturus Therapeutics has a consensus price target of $25.44, suggesting a potential upside of 240.62%. Given Arcturus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Arcturus Therapeutics is more favorable than Schrodinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.67

Schrodinger has a net margin of -40.61% compared to Arcturus Therapeutics' net margin of -143.80%. Schrodinger's return on equity of -30.85% beat Arcturus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Schrodinger	-40.61%	-30.85%	-15.32%
Arcturus Therapeutics	-143.80%	-36.55%	-28.40%

In the previous week, Arcturus Therapeutics had 4 more articles in the media than Schrodinger. MarketBeat recorded 10 mentions for Arcturus Therapeutics and 6 mentions for Schrodinger. Schrodinger's average media sentiment score of 0.34 beat Arcturus Therapeutics' score of -0.01 indicating that Schrodinger is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Schrodinger	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcturus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

79.1% of Schrodinger shares are held by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are held by institutional investors. 10.1% of Schrodinger shares are held by insiders. Comparatively, 17.8% of Arcturus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Arcturus Therapeutics has lower revenue, but higher earnings than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Schrodinger	$254.91M	3.46	-$103.26M	-$1.41	N/A
Arcturus Therapeutics	$82.03M	2.59	-$65.78M	-$2.81	N/A

Schrodinger has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market. Comparatively, Arcturus Therapeutics has a beta of 2.43, meaning that its stock price is 143% more volatile than the broader market.

Summary

Arcturus Therapeutics beats Schrodinger on 10 of the 17 factors compared between the two stocks.

Get Arcturus Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARCT vs. The Competition

Export

Metric	Arcturus Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$212.32M	$3.31B	$6.37B	$12.30B
Dividend Yield	N/A	2.32%	2.80%	5.26%
P/E Ratio	-2.66	18.50	20.66	25.27
Price / Sales	2.59	184.42	532.07	62.46
Price / Cash	N/A	121.77	42.43	54.86
Price / Book	1.11	6.63	9.87	6.90
Net Income	-$65.78M	$24.40M	$3.57B	$334.66M
7 Day Performance	-18.98%	4.14%	0.23%	0.12%
1 Month Performance	-15.59%	-4.80%	-2.54%	-0.18%
1 Year Performance	-35.88%	62.87%	33.54%	30.62%

Arcturus Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARCT Arcturus Therapeutics	2.2271 of 5 stars	$7.47 -4.6%	$25.44 +240.6%	-35.9%	$212.32M	$82.03M	N/A	180	Analyst Revision
CVAC CureVac	N/A	$4.66 flat	$6.83 +46.6%	N/A	$1.05B	$70.74M	6.47	880
AKTS Aktis Oncology	1.6864 of 5 stars	$18.27 -1.8%	$32.00 +75.2%	N/A	$993.30M	$6.50M	N/A	76	Earnings Report Analyst Forecast
ALVO Alvotech	3.3103 of 5 stars	$3.59 +10.1%	$7.60 +111.7%	-68.4%	$983.89M	$588.90M	N/A	1,460	Gap Up
PHAT Phathom Pharmaceuticals	2.904 of 5 stars	$12.22 +0.5%	$25.00 +104.6%	+190.2%	$969.83M	$175.11M	N/A	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARCT) was last updated on 5/17/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arcturus Therapeutics (ARCT) Competitors

ARCT vs. CVAC, AKTS, ALVO, PHAT, and SDGR

How does Arcturus Therapeutics compare to CureVac?

Summary

How does Arcturus Therapeutics compare to Aktis Oncology?

Summary

How does Arcturus Therapeutics compare to Alvotech?

Summary

How does Arcturus Therapeutics compare to Phathom Pharmaceuticals?

Summary

How does Arcturus Therapeutics compare to Schrodinger?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARCT vs. The Competition

Arcturus Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arcturus Therapeutics (ARCT) Competitors

ARCT vs. CVAC, AKTS, ALVO, PHAT, and SDGR

How does Arcturus Therapeutics compare to CureVac?

Which has higher valuation & earnings, CVAC or ARCT?

Which has more volatility & risk, CVAC or ARCT?

Is CVAC or ARCT more profitable?

Do analysts prefer CVAC or ARCT?

Does the media refer more to CVAC or ARCT?

Do institutionals and insiders have more ownership in CVAC or ARCT?

Summary

How does Arcturus Therapeutics compare to Aktis Oncology?

Does the media favor ARCT or AKTS?

Which has stronger earnings & valuation, ARCT or AKTS?

Do analysts recommend ARCT or AKTS?

Do institutionals & insiders hold more shares of ARCT or AKTS?

Is ARCT or AKTS more profitable?

Summary

How does Arcturus Therapeutics compare to Alvotech?

Which has higher earnings & valuation, ARCT or ALVO?

Do analysts rate ARCT or ALVO?

Do insiders and institutionals hold more shares of ARCT or ALVO?

Is ARCT or ALVO more profitable?

Which has more volatility & risk, ARCT or ALVO?

Does the media refer more to ARCT or ALVO?

Summary

How does Arcturus Therapeutics compare to Phathom Pharmaceuticals?

Which has higher earnings & valuation, ARCT or PHAT?

Do analysts rate ARCT or PHAT?

Do insiders and institutionals hold more shares of ARCT or PHAT?

Is ARCT or PHAT more profitable?

Which has more volatility & risk, ARCT or PHAT?

Does the media refer more to ARCT or PHAT?

Summary

How does Arcturus Therapeutics compare to Schrodinger?

Do analysts prefer SDGR or ARCT?

Is SDGR or ARCT more profitable?

Does the media prefer SDGR or ARCT?

Do institutionals and insiders hold more shares of SDGR or ARCT?

Which has better earnings & valuation, SDGR or ARCT?

Which has more volatility & risk, SDGR or ARCT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARCT vs. The Competition

Arcturus Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools